Clémence David's research while affiliated with Université Paris-Saclay and other places

Publication (1)

Full-text available
Background Anti-PD-(L)1 treatment is indicated for patients with mismatch repair-deficient (MMRD) tumors, regardless of tumor origin. However, the response rate is highly heterogeneous across MMRD tumors. The objective of the study is to find a score that predicts anti-PD-(L)1 response in patients with MMRD tumors.Methods Sixty-one patients with va...


... People with a higher total tumor burden tend to have a worse prognosis and a lower likelihood of surviving compared with those with a lower total tumor burden. [7][8][9] Patient-centered parameters also appear to be prognostic for survival. Therefore, body mass index (BMI) was higher in patients with melanoma treated by anti-PD-1 checkpoint inhibitors who had a better survival 10 or had early acute limiting toxicity. ...